Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Artrya Limited ( (AU:AYA) ) has issued an update.
Artrya Limited announced the issuance of 437,856 ordinary shares following the exercise of vested employee incentive securities, including restricted stock units and performance rights. This move reflects the company’s ongoing commitment to incentivizing its workforce as it continues to expand its presence in the medical technology industry, particularly in the area of coronary artery disease management.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$2.21 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited is an Australian medical technology company specializing in AI-powered solutions for the detection and management of coronary artery disease. The company offers a proprietary software platform that analyzes coronary CT scans to identify biomarkers of heart disease, aiding clinicians in more accurate and efficient diagnosis. Artrya is focused on advancing cardiac care through innovative technology, with ongoing regulatory and commercial efforts in key international markets.
Average Trading Volume: 244,279
Technical Sentiment Signal: Buy
Find detailed analytics on AYA stock on TipRanks’ Stock Analysis page.